koko体育app

欢迎来到《koko体育app 学报（医学版）》
张雪, 陈思敏, 郭军, 等. 新型凝血标记物在肝移植术后早期并发症中的应用价值[J]. koko体育app 学报（医学版）, 2023, 54(5): 1024-1029. DOI:
引用本文: 张雪, 陈思敏, 郭军, 等. 新型凝血标记物在肝移植术后早期并发症中的应用价值[J]. koko体育app 学报（医学版）, 2023, 54(5): 1024-1029. DOI:
ZHANG Xue, CHEN Simin, GUO Jun, et al. Application Value of Novel Coagulation Markers in Predicting Postoperarative Complications in the Early Stage After Liver Transplantation[J]. Journal of Sichuan University (Medical Sciences), 2023, 54(5): 1024-1029. DOI:
Citation: ✃ ZHANG Xue, CHEN Simin, GUO Jun, et al. Application Value of Novel Coagulation Markers in Predicting Postoperarative Complications in the Early Stage After Liver Transplantation[J]. Journal of Sichuan University (Medical Sciences), 2023, 54(5): 1024-1029. DOI:

新型凝血标记物在肝移植术后早期并发症中的应用价值

Application Value of Novel Coagulation Markers in Predicting Postoperarative Complications in the Early Stage After Liver Transplantation

  • 摘要:
      目的  探讨凝血酶-抗凝血酶复合物（thrombin-antithrombin complex, TAT）、纤溶酶-α2抗纤溶酶复合物（plasmin-α2-plasmin inhibitor complex, PIC）、可溶性血栓调节蛋白（soluble thrombomodulin, sTM）和组织型纤溶酶原激活剂-抑制剂复合物（tissue plasminogen activator-inhibitor complex, tPAIC）与肝移植术后早期并发症的关系。
      方法  分析 2021年12月–2022年11月koko体育app 华西医院重症医学科（intensive care unit, ICU）收治的130例肝移植术后患者围手术期的临床资料（包括血浆TAT、PIC、sTM和tPAIC）。根据患者术后30 d内是否发生Clavien-Dindo (CD) Ⅲb级及以上并发症，将患者分为并发症组和无并发症组。单因素分析及二元多因素logistic回归模型确定肝移植术后30 d内并发症的危险因素。
      结果  肝移植术后30 d内CDⅢb级及以上并发症的发生率为33.1%（43/130）。并发症组患者MELD评分、手术时间、术中红细胞用量、术中血浆用量以及术后ICU入院时血浆TAT、PIC、sTM和tPAIC均高于无并发症组（P<0.05）。logistic回归显示移植期间每输注1 U红细胞，肝移植术后30 d内并发症概率增加15.1%〔95%置信区间（confidence interval, CI）：1.070～1.239，P<0.001 〕，术后ICU入院时血浆sTM每增加1 TU/mL，肝移植术后30 d内并发症概率增加13.7%（95%CI：1.060～1.220，P<0.001）。
      结论  肝移植术后ICU入院时血浆sTM是肝移植术后30 d内并发症的重要危险因素，对sTM的额外评估可能有助于预测肝移植术后早期的并发症。
     
    Abstract:
      Objective  To investigate the relationship between thrombin-antithrombin complex (TAT), plasmin-α2-plasmininhibitor complex (PIC), soluble thrombomodulin (sTM), and tissue plasminogen activator-inhibitor complex (tPAIC) and postoperative complications in the early stage after liver transplantation (LT).
      Methods  We analyzed the perioperative clinical data, including plasma TAT, PIC, sTM, and tPAIC, of 130 post-LT patients admitted to the intensive care unit (ICU), West China Hospital, Sichuan University between December 2021 and November 2022. Patients were divided into two groups, a complication group and a non-complication group, according to whether they experienced complications of Clavien-Dindo (CD) grade Ⅲb and above within 30 days after the surgery. Univariate analysis and binary multivariate logistic regression models were used to determine the risk factors for complications within 30 days post-LT.
      Results  The incidence of complications of CD grade Ⅲb and above within 30 days post-LT was 33.1% (43/130). Patients in the complication group had significantly higher scores for the Model for End-Stage Liver Disease (MELD), operative time, intraoperative red blood cell transfusion volume, intraoperative plasma transfusion volume, and plasma TAT, PIC, sTM and tPAIC measured at the time of admission to ICU after the operation than those in the non-complication group did (all P<0.05). Logistic regression showed that for every single U of red blood cells transfused during the transplant surgery, the probabilities of complications within 30 days post-LT increased by 15.1% (95% confidence interval CI: 1.070-1.239, P<0.001) and for the increase of every single TU/mL of plasma sTM measured upon post-LT admission to ICU, the probabilities of complications increased by 13.7% (95% CI: 1.060-1.220, P<0.001).
      Conclusion  Plasma sTM measured upon admission to ICU after LT is an independent risk factor for complications within 30 days post-LT, and additional assessment of sTM may help predict complications in the early stage post-LT.
     
    • HTML全文
© 2023 《koko体育app 学报（医学版）》编辑部　版权所有 cc

开放获取ꦬ 本文遵循知识共享署名—非商业性使用4.0国际许可协议（CC BY-NC 4.0），允许第三方对本刊发表的论文自由共享（即在任何媒介以任何形式复制、发行原文）、演绎（即修改、转换或以原文为基础进行创作），必须给出适当的署名，提供指向本文许可协议的链接，同时标明是否对原文作了修改；不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问

/

返回文章
返回
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"}); koko体育-koko体育app koko体育-koko体育网页版koko体育app koko体育-全站app下载(官网) m6米乐app|下载 m6米乐app|主頁欢迎您!!